Pharmacy spending is once again the fastest‑growing component of employer health plans. Specialty drugs now account for more than half of total pharmacy spend, and GLP‑1 medications for diabetes and weight management are reshaping budgets. Employers are feeling the pressure: rising premiums, unpredictable claims, and employee expectations for access to high‑cost therapies.

The challenge is no longer simply “managing pharmacy costs.” It’s building a sustainable strategy that balances affordability, access, and long‑term health outcomes.

Why Costs Are Rising So Quickly

Three forces are driving the current surge:

• GLP‑1 medications: Demand for weight‑loss and metabolic drugs is exploding, with monthly costs often exceeding $1,000 per member.
• Specialty pharmacy inflation: Gene therapies, oncology drugs, and autoimmune treatments continue to rise in price.
• PBM reform and transparency rules: While positive for long‑term accountability, these changes are shifting pricing structures in ways employers are still adjusting to.

Employers need a multi‑layered strategy — not a single solution — to stay ahead of these trends.

Rethinking Pharmacy Benefit Management

Traditional PBM contracts often obscure true costs. Employers are increasingly turning to transparent or pass‑through PBMs that eliminate spread pricing and provide clearer insight into rebates and dispensing fees. This shift allows employers to understand what they’re actually paying for and identify opportunities for savings.

Some employers are also carving out specialty pharmacy benefits to gain more control over pricing and utilization. Specialty carve‑outs can reduce costs, but they require careful coordination to avoid gaps in care.

Alternative Funding Models: A Growing Trend

As specialty drug costs rise, employers are exploring alternative funding arrangements. These programs can help offset the cost of high‑cost medications, particularly for rare diseases or complex conditions.

Common approaches include:

• Manufacturer assistance programs
• Specialty drug carve‑outs
• Outcomes‑based contracts tied to clinical results

These models can reduce immediate financial pressure, but employers must evaluate administrative complexity and potential compliance considerations.

Managing GLP‑1 Demand Responsibly

GLP‑1 medications are transforming metabolic health, but they also pose a significant budget challenge. Employers are adopting new strategies to manage demand:

• Clinical criteria to ensure appropriate use
• Step therapy requiring lower‑cost alternatives first
• Lifestyle and coaching programs to support long‑term success

The goal is not to deny access, but to ensure that treatment is medically appropriate and supported by comprehensive care.

Empowering Employees Through Better Navigation

Employees often struggle to understand their pharmacy options. Employers can reduce costs and improve outcomes by helping employees make informed decisions. Tools such as price‑comparison apps, pharmacist hotlines, and digital navigation platforms can guide employees toward lower‑cost alternatives and preferred pharmacies.

Education is equally important. When employees understand how formularies work and why certain drugs require prior authorization, they are more likely to engage in cost‑effective care.

The Bottom Line

Pharmacy costs will continue to rise, but employers have more tools than ever to manage them. Transparent PBM contracts, alternative funding models, responsible GLP‑1 management, and employee navigation support can all help create a sustainable pharmacy strategy. The key is taking a proactive, data‑driven approach that balances cost control with employee well‑being.

For more Employee Benefits resources, contact INSURICA today.

Copyright © 2026 Smarts Publishing. This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice.